

Miren Ettcheto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4455335/publications.pdf>

Version: 2024-02-01

71
papers

3,413
citations

185998

28
h-index

149479

56
g-index

74
all docs

74
docs citations

74
times ranked

4896
citing authors

#	ARTICLE	IF	CITATIONS
1	Metal-Based Nanoparticles as Antimicrobial Agents: An Overview. <i>Nanomaterials</i> , 2020, 10, 292.	1.9	769
2	Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APP ^{swe} /PS1 ^{dE9} Alzheimer's disease mice model. <i>Journal of Controlled Release</i> , 2019, 301, 62-75.	4.8	207
3	Current Research Therapeutic Strategies for Alzheimer's Disease Treatment. <i>Neural Plasticity</i> , 2016, 2016, 1-15.	1.0	200
4	Memantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: in vitro and in vivo characterization. <i>Journal of Nanobiotechnology</i> , 2018, 16, 32.	4.2	163
5	Memantine for the Treatment of Dementia: A Review on its Current and Future Applications. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1223-1240.	1.2	150
6	Current Applications of Nanoemulsions in Cancer Therapeutics. <i>Nanomaterials</i> , 2019, 9, 821.	1.9	147
7	Advanced Formulation Approaches for Ocular Drug Delivery: State-Of-The-Art and Recent Patents. <i>Pharmaceutics</i> , 2019, 11, 460.	2.0	115
8	PEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen in vitro, ex vivo and in vivo characterization. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 145, 241-250.	2.5	108
9	Long-term exposition to a high fat diet favors the appearance of I ² -amyloid depositions in the brain of C57BL/6J mice. A potential model of sporadic Alzheimer's disease. <i>Mechanisms of Ageing and Development</i> , 2017, 162, 38-45.	2.2	79
10	Memantine-Loaded PEGylated Biodegradable Nanoparticles for the Treatment of Glaucoma. <i>Small</i> , 2018, 14, 1701808.	5.2	77
11	Current advances in the development of novel polymeric nanoparticles for the treatment of neurodegenerative diseases. <i>Nanomedicine</i> , 2020, 15, 1239-1261.	1.7	68
12	New potential strategies for Alzheimer's disease prevention: pegylated biodegradable dexibuprofen nanospheres administration to APP ^{swe} /PS1 ^{dE9} . <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 1171-1182.	1.7	64
13	Masitinib for the treatment of mild to moderate Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 587-596.	1.4	63
14	Epigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1073-1085.	1.7	60
15	Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. <i>Journal of Nanobiotechnology</i> , 2021, 19, 122.	4.2	60
16	ADAM10 in Alzheimer's disease: Pharmacological modulation by natural compounds and its role as a peripheral marker. <i>Biomedicine and Pharmacotherapy</i> , 2019, 113, 108661.	2.5	52
17	Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APP ^{swe} /PS1 ^{dE9} Mice. <i>Molecular Neurobiology</i> , 2020, 57, 1814-1827.	1.9	51
18	Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 233-251.	1.2	46

#	ARTICLE	IF	CITATIONS
19	Review of the advances in treatment for Alzheimer disease: strategies for combating β -amyloid protein. <i>Neurología (English Edition)</i> , 2018, 33, 47-58.	0.2	46
20	The Implication of the Brain Insulin Receptor in Late Onset Alzheimer's Disease Dementia. <i>Pharmaceuticals</i> , 2018, 11, 11.	1.7	45
21	Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 812-839.	2.9	45
22	Dexibuprofen Biodegradable Nanoparticles: One Step Closer towards a Better Ocular Interaction Study. <i>Nanomaterials</i> , 2020, 10, 720.	1.9	44
23	The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 236.	1.7	40
24	State-of-the-art polymeric nanoparticles as promising therapeutic tools against human bacterial infections. <i>Journal of Nanobiotechnology</i> , 2020, 18, 156.	4.2	38
25	Dexibuprofen prevents neurodegeneration and cognitive decline in APP ^{swe} /PS1 ^{dE9} through multiple signaling pathways. <i>Redox Biology</i> , 2017, 13, 345-352.	3.9	36
26	Benzodiazepines and Related Drugs as a Risk Factor in Alzheimer's Disease Dementia. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 344.	1.7	35
27	Experimental Models for Aging and their Potential for Novel Drug Discovery. <i>Current Neuropharmacology</i> , 2018, 16, 1466-1483.	1.4	35
28	The role of leptin in the sporadic form of Alzheimer's disease. Interactions with the adipokines amylin, ghrelin and the pituitary hormone prolactin. <i>Life Sciences</i> , 2015, 140, 19-28.	2.0	34
29	JNK1 inhibition by Licochalcone A leads to neuronal protection against excitotoxic insults derived of kainic acid. <i>Neuropharmacology</i> , 2018, 131, 440-452.	2.0	28
30	Lipid Nanoparticles for the Posterior Eye Segment. <i>Pharmaceutics</i> , 2022, 14, 90.	2.0	28
31	Epilepsy in Neurodegenerative Diseases: Related Drugs and Molecular Pathways. <i>Pharmaceuticals</i> , 2021, 14, 1057.	1.7	27
32	Surface Functionalization of PLGA Nanoparticles to Increase Transport across the BBB for Alzheimer's Disease. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 4305.	1.3	26
33	Targeting brain Renin-Angiotensin System for the prevention and treatment of Alzheimer's disease: Past, present and future. <i>Ageing Research Reviews</i> , 2022, 77, 101612.	5.0	26
34	Peripheral and Central Effects of Memantine in a Mixed Preclinical Mice Model of Obesity and Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 7327-7339.	1.9	24
35	Early Preclinical Changes in Hippocampal CREB-Binding Protein Expression in a Mouse Model of Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018, 55, 4885-4895.	1.9	21
36	JNK Isoforms Are Involved in the Control of Adult Hippocampal Neurogenesis in Mice, Both in Physiological Conditions and in an Experimental Model of Temporal Lobe Epilepsy. <i>Molecular Neurobiology</i> , 2019, 56, 5856-5865.	1.9	20

#	ARTICLE	IF	CITATIONS
37	Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APP ^{swe} /PS1 ^{dE9} mice. <i>Experimental Gerontology</i> , 2015, 65, 69-78.	1.2	19
38	Evaluation of the Role of JNK1 in the Hippocampus in an Experimental Model of Familial Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2016, 53, 6183-6193.	1.9	19
39	Role of JNK isoforms in the kainic acid experimental model of epilepsy and neurodegeneration. <i>Frontiers in Bioscience - Landmark</i> , 2017, 22, 795-814.	3.0	19
40	A metabolic perspective of late onset Alzheimer's disease. <i>Pharmacological Research</i> , 2019, 145, 104255.	3.1	19
41	Metformin a Potential Pharmacological Strategy in Late Onset Alzheimer's Disease Treatment. <i>Pharmaceuticals</i> , 2021, 14, 890.	1.7	19
42	Role of c-Jun N-Terminal Kinases (JNKs) in Epilepsy and Metabolic Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 255.	1.8	18
43	Epigallocatechin-3-gallate PEGylated poly(lactic-co-glycolic) acid nanoparticles mitigate striatal pathology and motor deficits in 3-nitropropionic acid intoxicated mice. <i>Nanomedicine</i> , 2021, 16, 19-35.	1.7	18
44	Anti-inflammatory role of Leptin in glial cells through p38 MAPK pathway inhibition. <i>Pharmacological Reports</i> , 2017, 69, 409-418.	1.5	15
45	Development and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment. <i>International Journal of Pharmaceutics</i> , 2022, 612, 121379.	2.6	15
46	Development of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation. <i>Pharmaceutics</i> , 2022, 14, 285.	2.0	15
47	Masitinib for the treatment of Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2021, 11, 263-276.	1.2	14
48	Biodegradable nanoparticles for the treatment of epilepsy: From current advances to future challenges. <i>Epilepsia Open</i> , 2022, 7, .	1.3	14
49	Pharmacological Strategies to Improve Dendritic Spines in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S91-S107.	1.2	13
50	A Chronological Review of Potential Disease-Modifying Therapeutic Strategies for Alzheimer's Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 1286-1299.	0.9	12
51	State of the Art on Toxicological Mechanisms of Metal and Metal Oxide Nanoparticles and Strategies to Reduce Toxicological Risks. <i>Toxics</i> , 2021, 9, 195.	1.6	11
52	The Ethyl Acetate Extract of Leaves of <i>Ugni molinae</i> Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APP ^{swe} /PS1 ^{dE9} Mice Fed with a High Fat Diet. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 1175-1191.	1.2	10
53	c-Jun N-terminal Kinase 1 ablation protects against metabolic-induced hippocampal cognitive impairments. <i>Journal of Molecular Medicine</i> , 2019, 97, 1723-1733.	1.7	10
54	Mice Lacking Functional Fas Death Receptors Are Protected from Kainic Acid-Induced Apoptosis in the Hippocampus. <i>Molecular Neurobiology</i> , 2015, 52, 120-129.	1.9	9

#	ARTICLE	IF	CITATIONS
55	Characterizing the multiple roles of FGF β 2 in SOD1 ^{G93A} ALS mice in vivo and in vitro. <i>Journal of Cellular Physiology</i> , 2019, 234, 7395-7410.	2.0	9
56	Involvement of JNK1 in Neuronal Polarization During Brain Development. <i>Cells</i> , 2020, 9, 1897.	1.8	8
57	Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment. <i>Pharmaceuticals</i> , 2021, 14, 220.	1.7	8
58	c-Jun N-Terminal Kinases in Alzheimer's Disease: A Possible Target for the Modulation of the Earliest Alterations. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S127-S139.	1.2	7
59	Dexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer's disease in metabolically stressed APP ^{swe} /PS1 ^{dE9} mice. <i>Cell and Bioscience</i> , 2021, 11, 141.	2.1	7
60	Role of brain c-Jun N-terminal kinase 2 in the control of the insulin receptor and its relationship with cognitive performance in a high-fat diet pre-clinical model. <i>Journal of Neurochemistry</i> , 2019, 149, 255-268.	2.1	6
61	Triple GLP-1/GIP/glucagon receptor agonists, a potential novel treatment strategy in Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 93-97.	1.9	5
62	The preclinical discovery and development of opicapone for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 993-1003.	2.5	5
63	Dual Mkk4 and Mkk7 Gene Deletion in Adult Mouse Causes an Impairment of Hippocampal Immature Granule Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9545.	1.8	2
64	Potential preventive disease-modifying pharmacological strategies to delay late onset Alzheimer's disease. <i>Neural Regeneration Research</i> , 2019, 14, 1721.	1.6	2
65	JNK1 and JNK3: divergent functions in hippocampal metabolic-cognitive function. <i>Molecular Medicine</i> , 2022, 28, 48.	1.9	2
66	Peroxisomal Proliferator-Activated Receptor β Deficiency Induces Cognitive Alterations. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
67	Isoform-selective as opposed to complete depletion of fibroblast growth factor 2 (FGF β 2) has no major impact on survival and gene expression in SOD1 G93A amyotrophic lateral sclerosis mice. <i>European Journal of Neuroscience</i> , 2019, 50, 3028-3045.	1.2	1
68	JNK isoforms control mammal adult hippocampal neurogenesis. <i>Mexican Journal of Medical Research ICSA</i> , 2020, 8, 5-12.	0.2	1
69	GSPE pre-treatment protects against long-term cafeteria diet-induced mitochondrial and inflammatory affectations in the hippocampus of rats. <i>Nutritional Neuroscience</i> , 2022, 25, 2627-2637.	1.5	1
70	EPIGALLOGATECHIN-3-GALLATE IMPROVES COGNITIVE DECLINE AND METABOLIC ALTERATIONS IN APP/PS1 FAMILIAL MODEL OF ALZHEIMER'S DISEASE FED WITH HIGH FAT DIET. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO1-1-32.	0.0	0
71	Therapeutic Strategies for Neurological Disorders: From Natural Compounds to Innovative Molecular Designs. <i>Current Pharmaceutical Design</i> , 2022, 28, i-ii.	0.9	0